Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 December 2022 | Story Rulanzen Martin | Photo Barend Nagel
From the left: Rulanzen Martin, Lacea Loader, Dr Nitha Ramnath, and Martie Nortjé.

Another year, another round of national and international awards for the Department of Communication and Marketing’s (DCM) campaigns and projects. This year saw DCM pick up an International Association of Business Communicators (IABC) Africa Silver Quill Award of Excellence for Communication Research for Narrative Building Storytelling. This project and subsequent award were in partnership with Development Communication Solutions (DevCom), led by Lacea Loader, Director: Communication and Marketing. 

During the 2022 annual Marketing, Advancement and Communication in Education (MACE) Excellence Awards, DCM won four excellence awards. Dr Nitha Ramnath, Deputy Director: Corporate Relations, won a Silver Award of Excellence for the 2021 Rector’s Concert, and a Bronze Award of Excellence for the 2022 Rector’s Concert. 

Lacea Loader and Martie Nortjé, Manager: Reputation, Brand and Marketing Management, won a Bronze Award of Excellence for the project ‘UFS – Our Story: The building and implementation of a brand narrative.’ Rounding up the UFS’ winning tally was Website Editor, Rulanzen Martin, who won a MACE Bronze Award of Excellence for the 2021 UFS Deaf Awareness Month (DAM) Campaign. The DAM campaign also received recognition during the 2021 IABC Silver Quill awards, where it won a Silver Quill Award of Excellence. 

Awards a perfect opportunity to benchmark 

“The awards give recognition to the communication efforts and endeavours undertaken by DCM as the strategic communication partner at the UFS; it also serves as a perfect opportunity to benchmark against peers and the industry. I am extremely proud of what the team has achieved,” says Loader.  “It is an honour when our projects receive awards, given the calibre of entries submitted for both the IABC and MACE awards programmes. The IABC awards programme is for all industries, while the MACE awards only recognise higher education institutions,” she says. 

For the 2022 MACE Excellence Awards, a total of 95 awards were awarded to 12 institutions from a total of 171 entries.

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept